grifols sustainable strategy


Grifols Buys Assets In The US And Canada For $460 M

Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year.The operation aligns with Grifols’ commitment to helping countries reach self-sufficiency of life-sustaining plasma-derived medicine. The acquisition includes 11 collection centers in the United States